in pursuit of autologous and allogeneic adoptive cell therapies to cure cancer
We are using our powerful drug discovery engine to develop a pipeline of innovative CAR and TCR adoptive cell therapy candidates in allogeneic formats.
We are preparing to file an IND in 2019 with the expectation to initiate trials for solid and liquid tumors.
Our mission is to change lives by providing patients around the world with best-in-class living drugs that bring faster treatment timelines and better tumor targeting for a wide range of cancers.
AgenTus Therapeutics was formed in 2017 as a subsidiary of Agenus Inc. to accelerate development of allogeneic adoptive cell therapies.
Today we are more than 40 employees working across three continents. Our expert scientists are working with world leading academic and commercial institutions to pioneer the delivery of living drugs to change lives of cancer patients.